April 4, 2022
InSysBio announces its participation in Quantitative Systems Pharmacology for Immuno-Oncology, a joint meeting of the EMBL's European Bioinformatics Institute (EMBL-EBI) & the UK QSP Network which is to be held 25th & 26th April 2022 in person at the EMBL-EBI Main Building, Wellcome Genome Campus, Hinxton, Cambridgeshire, UK, and online via Zoom.
Oleg Demin Jr, InSysBio Scientific & Marketing Director, Oncology & Immuno-Oncology, will give a talk in frames of Theme 1: Combination Therapy.
Monday, April 25, 11:20-11:45
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | December 2021 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
| ||
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
|
13
|
14
|
15
|
16
1.
16 Dec 2021 13:02
The launch of fIVE DB facilitates calibration of biomodels
InSysBio now presents its new QSP modeling tool, fIVE DB. The name of the database derives from In Vitro Experiments DataBase. fIVE DB is a repository of kinetic data for Systems Biology Modeling.
|
17
|
18
|
19
|
|
20
|
21
|
22
|
23
1.
23 Dec 2021 17:13
InSysBio to update CYTOCON DB and CYTOCON DB Open
CYTOCON DB is a database of human baseline concentrations of cytokines and cells measured in different tissues. CYTOCON DB Open is a version of the database designed for public use.
|
24
|
25
|
26
|
|
27
|
28
|
29
|
30
|
31
| ||
Thank you for your message! We will get back to you shortly.
